-
Treatment of the third clinical trial participant, required to complete the final dose escalation cohort in the CHM 1101 Phase 1A clinical trial, has been completed at City of Hope
-
This final dose cohort received CHM 1101 cells at a total dose of 440 X 106 CHM 1101 CAR T cells through dual routes of administration
-
Safety and efficacy to be assessed prior to the end of 2023
-
Phase 1B trial ongoing at the Sarah Cannon Transplant & Cellular Therapy Program at St David’s South Austin Medical Center
-
The Phase 1A and 1B trials will determine a recommended Phase 2 dose and administration schedule
Sydney, Australia, 29 August 2023: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce the successful treatment of the third participant, required to complete the fourth and final planned dose escalation cohort, in a Phase 1A dose escalation study being conducted at City of Hope evaluating the safety and maximum tolerated dose of Chimeric’s CHM 1101 (CLTX CAR T) in patients with recurrent or progressive glioblastoma (GBM).
For more information, download the attached PDF.
Download this document
